NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ABBV

Abbvie Inc

Jul 14 • 04:00PM ET

191.52

Dollar change -0.93
Percentage change -0.48	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: JNJ PFE MRK LLY BMY GILD AMGN REGN VRTX BIIB

| Held by: VTI VOO SPY IVV VTV SCHD XLV VIG IWF VYM

Scroll to Statements

Index	S&P 500	P/E	81.66	EPS (ttm)	2.35	Insider Own	0.09%	Shs Outstand	1.77B	Perf Week	2.07%
Market Cap	338.30B	Forward P/E	13.67	EPS next Y	14.01	Insider Trans	-14.92%	Shs Float	1.76B	Perf Month	0.01%
Enterprise Value	403.06B	PEG	5.35	EPS next Q	3.00	Inst Own	74.98%	Short Float	0.90%	Perf Quarter	9.94%
Income	4.16B	P/S	5.90	EPS this Y	19.39%	Inst Trans	1.69%	Short Ratio	2.29	Perf Half Y	7.29%
Sales	57.37B	P/B	238.22	EPS next Y	15.99%	ROA	2.92%	Short Interest	15.95M	Perf YTD	7.78%
Book/sh	0.80	P/C	65.36	EPS next 5Y	15.26%	ROE	88.15%	52W High	218.66 -12.41%	Perf Year	13.91%
Cash/sh	2.93	P/FCF	21.99	EPS past 3/5Y	-28.18% -14.67%	ROIC	6.30%	52W Low	163.81 16.92%	Perf 3Y	26.00%
Dividend Est.	6.51 (3.40%)	EV/EBITDA	15.54	Sales past 3/5Y	0.08% 11.11%	Gross Margin	70.80%	Volatility	2.38% 2.23%	Perf 5Y	92.77%
Dividend TTM	6.38 (3.33%)	EV/Sales	7.03	EPS Y/Y TTM	-30.21%	Oper. Margin	30.74%	ATR (14)	4.29	Perf 10Y	180.74%
Dividend Ex-Date	Jul 15, 2025	Quick Ratio	0.64	Sales Y/Y TTM	5.45%	Profit Margin	7.24%	RSI (14)	55.37	Recom	1.87
Dividend Gr. 3/5Y	5.81% 7.46%	Current Ratio	0.76	EPS Q/Q	-6.05%	SMA20	1.75%	Beta	0.50	Target Price	214.08
Payout	263.15%	Debt/Eq	49.22	Sales Q/Q	8.39%	SMA50	2.10%	Rel Volume	0.58	Prev Close	192.45
Employees	55000	LT Debt/Eq	45.44	Earnings	Jul 31 BMO	SMA200	1.77%	Avg Volume	6.97M	Price	191.52
IPO	Dec 10, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.39% 3.22%	Trades		Volume	4,053,666	Change	-0.48%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-25	Downgrade	Citigroup	Buy → Neutral	$205
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight	$210
Dec-10-24	Resumed	BofA Securities	Neutral	$191
Dec-05-24	Downgrade	Daiwa Securities	Outperform → Neutral	$180
Nov-22-24	Upgrade	Leerink Partners	Market Perform → Outperform	$206
Nov-15-24	Initiated	Wolfe Research	Outperform	$205
Nov-04-24	Upgrade	Argus	Hold → Buy
Oct-17-24	Initiated	Bernstein	Mkt Perform	$203
Jun-05-24	Upgrade	HSBC Securities	Hold → Buy	$185
May-17-24	Initiated	Cantor Fitzgerald	Overweight	$200
Jan-29-24	Upgrade	William Blair	Mkt Perform → Outperform
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Dec-11-23	Upgrade	Goldman	Neutral → Buy
Nov-09-23	Initiated	Deutsche Bank	Hold	$150
Oct-30-23	Upgrade	Barclays	Equal Weight → Overweight	$160 → $170
Oct-20-23	Resumed	UBS	Neutral	$157 → $150
Sep-29-23	Initiated	Raymond James	Outperform	$177
Jul-25-23	Initiated	William Blair	Mkt Perform
Jul-14-23	Initiated	HSBC Securities	Buy	$167
Apr-05-23	Downgrade	Argus	Buy → Hold

Show Previous Ratings

Today 11:30AM	AbbVie (ABBV) Updates 2025 EPS Guidance with $823M IPR&D Expense (Insider Monkey)
Jul-12-25 06:40AM	3 Dividend Growth Stocks to Buy and Hold (Motley Fool)
05:15AM	The Smartest Dividend Stocks to Buy With $300 Right Now (Motley Fool)
Jul-11-25 05:35PM	Refresh Releases First of its Kind Eye Drop for Dry Eyes (PR Newswire)
10:00AM	ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now? (Zacks)
04:38AM	Loading…
04:38AM	IGI and AbbVie sign licence deal for cancer and autoimmune therapy (Pharmaceutical Technology)
04:05AM	Ulcerative Colitis Drug Market Analysis and Forecast, 2025-2035 \| Anti-TNF a Agents and Interleukin Antagonists Spearhead Therapeutic Developments (GlobeNewswire)
04:01AM	Psoriatic Arthritis Market Report 2025-2035 \| Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma (GlobeNewswire)
03:55AM	What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill (Motley Fool)
Jul-10-25 05:45PM	AbbVie (ABBV) Laps the Stock Market: Here's Why (Zacks)
03:53PM	Wall Street Stunned: AbbVie Drops $700M on a Little-Known Indian Cancer Drug (GuruFocus.com)
02:58PM	Final Trades: Abbvie, Boeing, Oracle and Joby Aviation (CNBC TV)
02:04PM	AbbVie Inc. (ABBV): A Bull Case Theory (Insider Monkey)
12:24PM	Tesla robotaxi, AbbVie licenses Glenmark cancer drug, McDonald's (Yahoo Finance Video)
11:42AM	Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38xBCMAxCD3 Trispecific Antibody (PR Newswire)
11:23AM	Loading…
11:23AM	Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody (PR Newswire)
07:30AM	AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38xBCMAxCD3 Trispecific Antibody (PR Newswire)
07:30AM	AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody (PR Newswire)
07:12AM	AbbVie to pay $700M for trispecific drug from Ichnos Glenmark (BioPharma Dive)
Jul-09-25 10:26AM	Morgan Stanley Maintained an Overweight Rating on AbbVie (ABBV) (Insider Monkey)
Jul-08-25 04:01PM	Stock market today: Dow, S&P 500 slip as Trump stays firm on August tariff deadline, announces copper duties (Yahoo Finance)
02:27PM	Stock market today: Dow, S&P 500, Nasdaq steady as Trump says he won't extend Aug. 1 tariff deadline (Yahoo Finance)
02:17PM	Uber's highs, Trump tariff warning, Wendys CEO heads to Hershey (Yahoo Finance Video)
09:15AM	Nocturia Market Research and Forecast Report 2025-2034, Featuring Leading Players - Urigen Pharmaceuticals, Glenmark Pharmaceuticals, AbbVie, Teva Pharmaceuticals (GlobeNewswire)
08:27AM	How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results? (Zacks)
05:32AM	AbbVie to Acquire Capstan Therapeutics for $2.1B, Boosting Autoimmune Pipeline (Insider Monkey)
04:00AM	Is biopharma dealmaking getting hot again? (Pharma Voice)
Jul-07-25 12:48PM	Prime Medicine stock soars amid gene editing sector momentum (Investing.com)
09:00AM	AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:35AM	Here's What to Expect From AbbVie's Next Earnings Report (Barchart)
06:40AM	Loading…
06:40AM	3 No-Brainer Stocks to Buy in July (Motley Fool)
Jul-06-25 08:45AM	2 Dividend Stocks to Buy for Decades of Passive Income (Motley Fool)
Jul-05-25 05:41AM	Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever (Motley Fool)
Jul-03-25 09:30AM	Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views? (Zacks)
08:20AM	Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth (Zacks)
Jul-02-25 07:30PM	3 Giant Dividend Stocks to Buy to Shield Your Portfolio Now (Barchart)
10:46AM	The Zacks Analyst Blog Highlights Alphabet, AbbVie and The Walt Disney (Zacks)
09:40AM	Why AbbVie (ABBV) is a Top Value Stock for the Long-Term (Zacks)
09:07AM	Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth? (Zacks)
08:46AM	Will AbbVie's Acquisition Spree Aid Pipeline Growth? (Zacks)
Jul-01-25 04:31PM	Top Stock Reports for Alphabet, AbbVie & Walt Disney (Zacks)
10:05AM	ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B (Zacks)
06:20AM	Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)? (Zacks)
Jun-30-25 10:07AM	Stocks See Support as Signs of Trade Progress Boost Market Sentiment (Barchart)
08:57AM	AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion (The Wall Street Journal)
08:42AM	AbbVie to buy Capstan for up to $2.1 billion in immunology push (Reuters)
08:31AM	AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology (PR Newswire)
08:25AM	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance (PR Newswire)
08:25AM	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVEDERM for the Improvement of Neck Appearance (PR Newswire)
08:00AM	AbbVie to Host Second-Quarter 2025 Earnings Conference Call (PR Newswire)
Jun-29-25 04:51AM	3 Dividend Stocks to Double Up on Right Now (Motley Fool)
Jun-28-25 05:49AM	Got $500? 2 Healthcare Stocks to Buy and Hold Forever (Motley Fool)
04:15AM	AbbVie's Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment (Insider Monkey)
Jun-27-25 05:45PM	AbbVie (ABBV) Stock Dips While Market Gains: Key Facts (Zacks)
10:08AM	AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock (Zacks)
Jun-26-25 04:45PM	Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role? (Investor's Business Daily)
09:50AM	Here's Why AbbVie (ABBV) is a Strong Momentum Stock (Zacks)
09:11AM	Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes (Investor's Business Daily)
Jun-25-25 10:15AM	Rosalind Franklin University Helix 51 Company UP Oncolytics Secures Wisconsin Economic Development Matching Grant to Advance Oncolytic Virus Therapy for Brain Cancer (PR Newswire)
08:58AM	Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer (GlobeNewswire)
03:27AM	After myriad failures, a new wave of ALS drugs approaches (Pharma Voice)
Jun-24-25 09:00AM	Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know (Zacks)
08:22AM	Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth? (Zacks)
05:51AM	Age-Related Vision Dysfunction Market Research 2025-2035 \| Kodiak Sciences, Genentech, and AbbVie Drive Innovations Through Advanced, Sustainable Solutions (GlobeNewswire)
Jun-23-25 09:15AM	J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications (Zacks)
Jun-20-25 11:53PM	Is AbbVie the Best Dividend Stock in Big Pharma Today? (Insider Monkey)
09:28AM	LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet? (Zacks)
08:00AM	AbbVie Declares Quarterly Dividend (PR Newswire)
Jun-19-25 10:06AM	AbbVies Phase III trial of atogepant for migraine meets primary goal (Clinical Trials Arena)
Jun-18-25 10:22AM	GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold? (Zacks)
07:15AM	AbbVie Announces New Data Demonstrating Atogepant (QULIPTA / AQUIPTA) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention (PR Newswire)
06:30AM	Proposed Crackdown on Pharma Ads Leaves Cable TV Fearing $10B Withdrawal (The Daily Upside)
06:20AM	Should You Invest in the Invesco Pharmaceuticals ETF (PJP)? (Zacks)
Jun-17-25 05:45PM	Here's Why AbbVie (ABBV) Fell More Than Broader Market (Zacks)
05:16PM	Trump's big beautiful bill: What the pharma industry is watching (Yahoo Finance Video)
03:22PM	3 Dividend Growth Stocks To Buy and Hold Forever (barchart.com)
11:18AM	AMD extends gains, solar stocks plummet, pharma stocks (Yahoo Finance Video)
10:30AM	AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study (Zacks)
10:12AM	RFK Jr. Plans Crackdown on Pharma Ads in Threat to $10 Billion Market (Bloomberg)
09:30AM	Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
09:05AM	AbbVie says Phase 3 Verona trial of venetoclax/azacitidine did not meet endpoint (TipRanks)
02:23AM	AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics (Insider Monkey)
Jun-16-25 09:46AM	EHA 2025: Genmab and AbbVies Epkinly outpaces BiTE rivals in r/r DLBCL trial (Clinical Trials Arena)
09:40AM	Here's Why AbbVie (ABBV) is a Strong Value Stock (Zacks)
09:06AM	5 Large Drug Stocks That Are Poised to Ride on Sector Recovery (Zacks)
09:00AM	Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE? (Zacks)
09:00AM	AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes (PR Newswire)
06:20AM	Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now? (Zacks)
Jun-13-25 04:18PM	AbbVie Secures FDA Approval to Expand Mavyret's Label (Insider Monkey)
02:24PM	Calls of the Day: Netflix, NRG Energy, Air Products, and Abbvie (CNBC TV)
04:28AM	FDA approves label expansion of AbbVie hepatitis C therapy (Pharmaceutical Technology)
Jun-12-25 03:41PM	Senators Propose Ban on Drug Advertising to Consumers (The Wall Street Journal)
01:59PM	Lawmakers push to ban direct-to-consumer drug advertising, WSJ reports (Investing.com)
12:36PM	Senators to Propose Ban on Drug Advertising to Consumers (The Wall Street Journal)
Jun-11-25 05:45PM	AbbVie (ABBV) Gains As Market Dips: What You Should Know (Zacks)
05:07PM	FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) (Benzinga)
12:31PM	U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus (PR Newswire)
10:57AM	Trump Wants Cheaper Drugs Like Europe Has. How It Works. (Barrons.com)
09:00AM	Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock (Zacks)
Jun-10-25 10:23AM	Top Cancer Stocks to Supercharge Your 2025 Portfolio (Zacks)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 31 '25	Option Exercise	79.02	25,700	2,030,814	112,066	Apr 02 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 31 '25	Sale	210.08	58,832	12,359,504	53,234	Apr 02 05:00 PM
Stewart Jeffrey Ryan	Officer	Mar 31 '25	Proposed Sale	210.09	58,832	12,359,897		Mar 31 05:30 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Mar 14 '25	Sale	212.34	17,644	3,746,527	11,577	Mar 18 05:00 PM
Reents Scott T	Officer	Mar 14 '25	Proposed Sale	212.35	17,644	3,746,628		Mar 14 04:34 PM
GONZALEZ RICHARD A	Director	Feb 28 '25	Sale	205.11	92,460	18,964,471	395,097	Mar 04 05:00 PM
GONZALEZ RICHARD A	Director	Mar 03 '25	Sale	210.53	6,168	1,298,549	388,929	Mar 04 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 03 '25	Option Exercise	159.88	18,008	2,879,040	22,627	Mar 04 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 03 '25	Sale	210.00	18,008	3,781,680	4,619	Mar 04 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 28 '25	Sale	206.30	9,892	2,040,722	4,619	Mar 04 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 03 '25	Sale	210.45	21,250	4,472,039	6,130	Mar 04 05:00 PM
GONZALEZ RICHARD A	Officer	Mar 03 '25	Proposed Sale	210.53	6,168	1,298,550		Mar 03 05:57 PM
PERRY C SIATIS	Officer	Mar 03 '25	Proposed Sale	210.00	18,008	3,781,680		Mar 03 04:28 PM
TIMOTHY RICHMOND	Officer	Mar 03 '25	Proposed Sale	210.46	21,250	4,472,184		Mar 03 04:08 PM
GONZALEZ RICHARD A	Officer	Feb 28 '25	Proposed Sale	205.11	92,460	18,964,882		Feb 28 05:37 PM
Buckbee Kevin K	SVP, CONTROLLER	Feb 26 '25	Option Exercise	98.48	16,260	1,601,313	28,906	Feb 28 05:00 PM
Buckbee Kevin K	SVP, CONTROLLER	Feb 26 '25	Sale	203.41	18,944	3,853,372	11,496	Feb 28 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Feb 26 '25	Option Exercise	114.36	22,210	2,539,936	66,494	Feb 28 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Feb 26 '25	Sale	202.90	29,917	6,070,036	44,284	Feb 28 05:00 PM
PERRY C SIATIS	Officer	Feb 28 '25	Proposed Sale	206.31	9,892	2,040,790		Feb 28 04:12 PM
Buckbee Kevin K	Officer	Feb 26 '25	Proposed Sale	203.41	18,944	3,853,398		Feb 26 05:47 PM
TIMOTHY RICHMOND	Officer	Feb 26 '25	Proposed Sale	202.90	29,917	6,070,176		Feb 26 04:04 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 20 '25	Sale	197.90	5,778	1,143,453	22,381	Feb 24 05:00 PM
PERRY C SIATIS	Officer	Feb 20 '25	Proposed Sale	197.90	5,778	1,143,492		Feb 20 04:10 PM
Buckbee Kevin K	SVP, CONTROLLER	Dec 16 '24	Option Exercise	93.50	1,800	168,300	8,783	Dec 18 05:00 PM
Buckbee Kevin K	SVP, CONTROLLER	Dec 16 '24	Sale	172.24	1,800	310,032	6,983	Dec 18 05:00 PM
Buckbee Kevin K	Officer	Dec 16 '24	Proposed Sale	172.25	1,800	310,045		Dec 16 05:34 PM
Hudson Thomas J	Officer	Aug 08 '24	Proposed Sale	189.08	49,170	9,297,210		Aug 08 05:40 PM
GONZALEZ RICHARD A	EXECUTIVE CHAIRMAN OF BOARD	Aug 05 '24	Sale	186.52	66,500	12,403,580	446,599	Aug 07 05:00 PM
Hudson Thomas J	Officer	Aug 07 '24	Proposed Sale	187.62	101,886	19,115,380		Aug 07 04:22 PM
GONZALEZ RICHARD A	Officer	Aug 05 '24	Proposed Sale	187.36	66,500	12,459,360		Aug 05 10:54 AM
GONZALEZ RICHARD A	EXECUTIVE CHAIRMAN OF BOARD	Jul 17 '24	Option Exercise	77.49	282,845	21,919,048	795,944	Jul 19 04:40 PM
GONZALEZ RICHARD A	EXECUTIVE CHAIRMAN OF BOARD	Jul 17 '24	Sale	175.00	282,845	49,497,875	513,099	Jul 19 04:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your FINVIZ experience